Bioatla Inc (BCAB NASDAQ) stock market data APIs
$1.3183
-0.06(-4.6%)
as of September 4, 2026
Try our APIs with
free plan!
Bioatla Inc Financial Data Overview
Price chart is built with
Anychart
BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC to treat melanoma and oropharyngeal squamous cell carcinoma. The company is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for treating melanoma, renal cell carcinoma, colorectal cancer, and NSCLC; BA3182, a bispecific candidate to treat adenocarcinomas; BA3361, a CAB-Nectin-4-ADC for treating tumors; BA3142, a dual-CAB T-cell engager targeting B7-H3, a protein expressed on various solid tumors; and preclinical candidate for CAB-Nectin 4 x CAB-CD3. The company was founded in 2007 and is headquartered in San Diego, California.
Prev. Close
1.3183
Open
1.2615
High
1.3819
Low
1.1703
52 wk Range
1.07-71.5
Market Cap
2 891 K
Shares Outstanding
1 666 K
Revenue
8 500 K
EPS
0.14
Beta
0.698
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Bioatla Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Bioatla Inc data using free add-ons & libraries
Get Bioatla Inc Fundamental Data
Bioatla Inc Fundamental data includes:
- Net Revenue: 8 500 K
- EBITDA: -30 830 000
- Earnings Per Share: -25
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-08-13
- EPS/Forecast: -8.5
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Bioatla Inc News
New
Context Expands Q2 Net Loss As Pipeline Advances; Stock Drops 23% In Overnight Market
(RTTNews) - Context Therapeutics Inc. (CNTX) reported financial results for the second quarter ended June 30, 2026, reflecting a wider year-over-year loss as it prepares to progress its clinical pipel...
Pre-Market Movers: BJDX, PMI, SBFM Drive Momentum
(RTTNews) - Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. ...
BioAtla Announces Share Consolidation
BioAtla, Inc. SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionall...
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla...
Get Bioatla Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
